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Background: To assess clinical outcomes following transcatheter aortic valve implantation (TAVI) according to the Valve Academic Research 
Consortium definitions.
Methods: All consecutive patients with native valve aortic stenosis treated with TAVI from November 2007 to September 2011 in our center 
utilizing either Edwards SAPIEN™ (ESV) or Medtronic CoreValve ReValving System® (MCV) were analyzed.
Results: In total, 347 patients were included in this analysis. The majority of cases used the transfemoral access site (n=283; 81.6%). The overall 
mean age was 79.5±7.0 years, logistic EuroSCORE 23.7±16.7% and STS-PROM score 8.9±8.7%. The median clinical follow-up length was 350 (IQR 
81-461) days. Thirty-day mortality was 4.9% in the whole study population with myocardial infarction rate 1.4% and stroke 0.9%. Life-threatening 
bleeding occurred in 24.3% and 14.5% had a major vascular complication. At one-year, all-cause mortality was 19.6%. Analysis according to valve 
type in the transfemoral population revealed no differences in combined safety or combined efficacy endpoints. However, there was a significantly 
higher rate of device success amongst the ESV group (96.0% vs. 89.0%; p=0.022) with additionally a significantly higher rate of conduction 
disturbances/arrhythmia (28.4% vs. 13.2%; p=0.002) as well as pacemaker implantation (25.7% vs. 5.7%; p<0.001) with MCV compared with ESV.
Conclusions: In our single center experience, TAVI was a relatively safe and effective procedure in patients with severe AS considered high-risk for 
SAVR, with a low mortality rate at 30-days and one-year follow-up and acceptable outcomes according to VARC definitions.
